Search MTNB
Matinas BioPharma Holdings, Inc.
NYSE · CIK 1582554
Last close2.64
Daily change+0.22 (9.09%)
10 Years gain-96.66%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
MTNB · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
60.3Momentum
100.0Acceleration
60.0Confidence
86.0Annual Revenue10
Quarterly Revenue24
Annual CFO11
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality18.2 / 25
Capital Efficiency1.8 / 20
Balance Sheet12.3 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 1103.0646 percentage points.
Share count reductionDiluted share count declined 97.9963%.
Warnings
High SBC · MEDIUMStock based compensation is high relative to revenue or FCF.
ROIC declining · MEDIUMROIC declined by 10.5697 percentage points.
Key Metrics
Revenue Growth TTM96.93%OK
Revenue CAGR 3Y90.58%OK
Gross Marginn/aMISSING
Operating Margin-1,081.1%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-397.41%OK
Incremental Operating Margin 3Y-432.47%OK
Net Debt / CFO1.16xOK
Diluted Share Growth 1Y-98%OK
SBC / Revenue235.71%OK
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | n/a | n/a | -$6.96M | -$7.01M | n/a | n/a | n/a | n/a | -967.18% | 5.47M |
| 2025 FY Dec 31, 2024 | n/a | n/a | -$24.59M | -$15.89M | n/a | n/a | n/a | n/a | -670.41% | 4.87M |
| 2024 FY Dec 31, 2023 | $1.10M | n/a | -$23.77M | -$15.28M | -$15.50M | n/a | -2,168.43% | -1,413.87% | -280.98% | 4.35M |
| 2023 FY Dec 31, 2022 | $3.19M | n/a | -$24.59M | -$19.16M | -$20.05M | n/a | -771.33% | -628.86% | -361.55% | 216.81M |
| 2022 FY Dec 31, 2021 | $33,000.00 | n/a | -$24.74M | -$15.22M | -$15.48M | n/a | -74,954.55% | -46,918.18% | -493.11% | n/a |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $2.16M | sum latest 4 fiscal quarters Revenue | OK | 0001493152-23-039892, 0001493152-24-018417 |
| Revenue Growth TTM | 96.93% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001493152-23-039892, 0001493152-24-018417 |
| Revenue CAGR 3Y | 90.58% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001641172-25-004882 |
| Revenue CAGR 5Y | 55.71% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001641172-25-004882 |
| Gross Profit CAGR 3Y | n/a | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | INSUFFICIENT_HISTORY | derived |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001493152-23-039892, 0001493152-24-018417 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Margin | -1,081.1% | Operating Income / Revenue | OK | 0001493152-23-039892, 0001493152-24-018417 |
| ROIC | -397.41% | NOPAT / Average Invested Capital | OK | 0001493152-23-039892, 0001493152-24-018417 |
| Net Debt / CFO | 1.16x | Net Debt / CFO | OK | 0001493152-24-045201, 0001493152-23-039892 |
| Current Ratio | 6.19x | Current Assets / Current Liabilities | OK | derived |
| SBC / Revenue | 235.71% | SBC / Revenue | OK | 0001493152-23-039892, 0001493152-24-018417 |
| Revenue per Diluted Share | $0.50 | Revenue / Diluted Shares | OK | 0001493152-23-039892, 0001493152-24-018417 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | 0001493152-23-039892, 0001493152-24-018417 |